Objective To investigate the clinical efficacy and related adverse reactions of the combination of camrelizumab with anlotinib as the third-line therapy on advanced non-small cell lung cancer. Methods We retrospectively analyzed the clinical data of 84 patients with advanced non-small cell lung cancer after second-line treatment. According to different treatment methods, 44 patients who received camrelizumab combined with anlotinib were included in the observation group, and 40 patients who received anlotinib alone were included in the control group. The PFS, ORR, DCR and incidence of adverse reactions were analyzed and compared between the two groups. Results The median PFS of the observation group was longer than that of the control group (7.0 vs. 5.6 months, P=0.001). No statistically significant difference was observed in ORR, DCR, the incidence of adverse reactions or the incidence of adverse reactions above grade 3 between two groups (all P > 0.05). Conclusion The clinical efficacy of camrelizumab combined with anlotinib as third-line therapy on advanced non-small cell lung cancer is better than anlotinib alone, and the safety is good.

Objective:To explore the application value of prognostic nutrition index (PNI) in predicting the quality of life in lung cancer patients undergoing palliative chemotherapy.Methods:Totally 89 lung cancer patients who underwent palliative chemotherapy in the First Affiliated Hospital of Zhengzhou University from June 2014 to June 2017 were selected using convenient sampling, and divided into high-PNI group and low-PNI group according to PNI. The quality of life was compared between the two groups. The Kaplan-Meier method was used to draw survival curves, and Log-Rank test was employed to compare the survival rates of the two groups.Results:Two of the 89 patients died during the study period, and all data of 87 patients were completed, including 56 in the high-PNI group and 31 in the low-PNI group. The overall quality of life score of (72.44±6.49) in the high-PNI group and (68.82±6.01) in the low-PNI group, and the difference was statistically significant ( t=2.557, P<0.05) . The half-year survival rates of the high-PNI and low-PNI groups were 87.50% and 82.14%; the one-year survival rates were 81.02% and 64.28%; and the two-year survival rates were 57.73% and 39.28%, respectively. The differences in survival rates between the two groups were statistically significant (Log-Rank=4.293, P<0.05) . Conclusions:The overall quality of life in lung cancer patients undergoing palliative chemotherapy with low PNI is lower than that of high PNI patients. PNI can be used as a prognostic indicator for lung cancer patients undergoing palliative chemotherapy.